EUVIMED · CrossrefZeitschrift
Onkologie
ISSN 1802-4475 · Solen s.r.o.
Neueste Artikel
Current options for adjuvant treatment of urothelial carcinomas
Immunotherapy in the treatment of metastatic urothelial carcinoma
Neoadjuvant therapy of bladder cancers
Radiotherapy as an organ-preserving approach in treating muscle-invasive bladder cancer
Venous access in oncology - the choice between PICC and port
Patient with primary metastasizing anorectal mucosal melanoma
Complete remission of metastatic squamous esophageal carcinoma
Management of epitheloid inflammatory myofibroblastic sarcoma of pulmonary origin
Current targeted therapy options in chronic lymphocytic leukemia
Rituximab-venetoclax in the second line of treatment of chronic lymphocytic leukemia in a patient with TP53 mutation
CAR T-lymphocytes in the treatment of non-Hodkgin's lymphoma: current perspectives
Novel therapeutical strategies in diffuse large B-cell lymphoma
The importance of the microbiome in hematooncology patients
Ruxolitinib in treating polycythemia vera: what is it that we do not know yet?
Skin care in oncology patients
Hepatocellular carcinoma - systemic treatment in 2024
Adverse effects of radiotherapy and radiobiological modelling
Hypophosphatemia - an overlooked electrolyte
Atypical intradermal smooth muscle tumor (cutaneous leiomyosarcoma): a case report
Coping strategies in older adults with cancer - implications for nursing care
Brief history of ovarian cancer treatment
Lung cancer screening and the Population pilot program for the early detection of lung cancer in the Czech Republic
What are the benefits of proton beam therapy for esophageal cancer?
Dose escalation in the treatment of NSCLC with proton radiotherapy
Hypofractionated proton radiotherapy for prostate cancer: six-year data
Proton therapy in the treatment of meningiomas
Feasibility, dosimetric evaluation and early results of proton radiotherapy in the treatment of bilateral breast cancer
Avelumab plus axitinib combination in treating metastatic renal cell carcinoma
Locally advanced pancreatic cancer - a complete morpho-metabolic response of primary tumor after non-surgical treatment
Pharmacological profile - trastuzumab emtansine
EUVIMED